Related Industry Reports:
- The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012
- BAFF (BLys) and APRIL: Emerging Targets for autoimmune disease & Cancer Therapeutics
- The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
- Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment Per Trial has Continued to Decline Over the Past Decade
- Biotech in Autoimmune and Inflammatory Disease 2006
Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases.
Autoimmunity 2010 Jul 29; In press
Zhou X, Kong N, Zou H, Brand D, Li X, Liu Z, Zheng S SG
Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, CA, 90033, USA.
Foxp3(+) T regulatory cell (Treg) subsets play a crucial role in the maintenance of immune homeostasis against self-antigens. The lack or dysfunction of these cells contributes to the pathogenesis and development of many autoimmune diseases. Therefore, manipulation of these cells may provide a novel therapeutic approach to treat autoimmune diseases. In this review, we provide current opinions concerning the classification, developmental, and functional characterization of Treg subsets. Particular emphasis will be focused on the therapeutic role of TGF-beta-induced CD4M(+) Foxp3(+) cells (iTregs) in established autoimmune disease. Moreover, the similarity and diversity of iTregs and naturally occurring, thymus-derived CD4(+) CD25(+) Foxp3(+) regulatory T cells (nTregs) will be discussed, including the finding that the pro-inflammatory cytokine IL-6 can convert nTregs to IL-17-producing cells, whereas iTregs induced by TGF-beta are resistant to the effects of this cytokine. Understanding these aspects may help to determine how Tregs can be used in the treatment of autoimmune diseases.
Keywords: TGF-beta autoimmune